Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/zepbound/california/west-covina
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in West Covina, CA

Verified Zepbound providers in West Covina, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
28
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
29 of 29 shown

Find a Zepbound provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /zepbound/california/{city}
Baldwin Park
34.08°N
33 →
El Monte
34.07°N
29 →
Glendora
34.14°N
23 →
Pomona
34.06°N
37 →
Whittier
33.97°N
25 →
Rosemead
34.07°N
29 →
§ 03Getting Zepbound in West Covina
29 providers · West Covina, CA

How to get Zepbound in West Covina.

29 GLP-1 prescribers and 7 local resource types are on record for West Covina, plus 3 nearby towns in the directory.

Prescribers in West Covina
29 prescribers
29 GLP-1 prescribers in West Covina, most listed as Family Medicine (15), Internal Medicine (9) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). Any California-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Baldwin Park (33 providers), El Monte (29 providers) and Glendora (23 providers).
Around the prescription in West Covina
7 listed nearby
23 dietitians, 2 nutritionists, 5 gyms, 3 fitness clubs, 4 trainers, 46 physiotherapists and 22 places to move are on record near West Covina.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in West Covina

West Covina, California has a population of 109,501 people. The adult obesity rate in West Covina is an age-adjusted estimate of 23.7%, 5.4 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 11.6% of adults in West Covina. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26% of adults in West Covina.

of West Covina adults have obesity
23.7%
diagnosed diabetes
11.6%
no regular physical activity
26%

Age-adjusted estimates for West Covina, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Zepbound in West Covina
2 nutritionists

The prescription is one part. Here is the rest, in West Covina.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near West Covina, CA, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Ashley Quinones
NUTRITIONIST
Nutritionist
1800 E Aroma Dr Apt 233
Call 626-417-3190NPI 1700567286
Tammy Tagge
NUTRITIONIST
Nutritionist · Education
703 N La Breda Ave
Call 626-840-8816NPI 1477383636

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Self Made Training Facility West Covina | Personal Fitness Center
FITNESS
4.2 on Google · 33 reviews
1705 W Garvey Ave N
Planet Fitness
GYM
4.0 on Google · 214 reviews
2630 E Workman Ave Ste 315 B
Website
Hourglass Lab - All Women’s Private Gym
GYM
4.7 on Google · 53 reviews
983 W San Bernardino Rd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in California

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in California
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in California
Clinics running GLP-1 programs, telehealth & in-person.
Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Zepbound in Alabama→Zepbound in Alaska→Zepbound in Arizona→Zepbound in Arkansas→Zepbound in California→Zepbound in Colorado→Zepbound in Connecticut→Zepbound in Delaware→Zepbound in Florida→Zepbound in Georgia→Zepbound in Hawaii→Zepbound in Idaho→Zepbound in Illinois→Zepbound in Indiana→Zepbound in Iowa→Zepbound in Kansas→Zepbound in Kentucky→Zepbound in Louisiana→Zepbound in Maine→Zepbound in Maryland→Zepbound in Massachusetts→Zepbound in Michigan→Zepbound in Minnesota→Zepbound in Mississippi→Zepbound in Missouri→Zepbound in Montana→Zepbound in Nebraska→Zepbound in Nevada→Zepbound in New Hampshire→Zepbound in New Jersey→Zepbound in New Mexico→Zepbound in New York→Zepbound in North Carolina→Zepbound in North Dakota→Zepbound in Ohio→Zepbound in Oklahoma→Zepbound in Oregon→Zepbound in Pennsylvania→Zepbound in Rhode Island→Zepbound in South Carolina→Zepbound in South Dakota→Zepbound in Tennessee→Zepbound in Texas→Zepbound in Utah→Zepbound in Vermont→Zepbound in Virginia→Zepbound in Washington→Zepbound in West Virginia→Zepbound in Wisconsin→Zepbound in Wyoming→
Related GLP-1 research
plateaus on Wegovy and Ozempic
The plateau playbook: dose, habits, and what the trials say.
the tirzepatide dosing schedule
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
§ 09Frequently asked: Zepbound in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]